The Parkinson’s Outcomes Project (POP) is the largest-ever clinical study of people with Parkinson’s disease (PD). Since the beginning of this groundbreaking initiative in 2009, Parkinson’s Foundation Centers of Excellence have been tracking and monitoring the care of more than 13,000 people in five countries with all stages of PD. The goal is to find the most effective therapies, study their benefits, and determine the best candidates for each treatment.
One of the findings of POP is that anxiety is a major factor affecting the overall health of people with PD. Worry about a health condition is normal, but when it becomes constant feelings of worry or nervousness beyond what is understandable, it may be anxiety, a mental health condition. Anxiety is not just a reaction to a diagnosis of PD or the daily stresses that accompany it but is also an integral part of the disease caused by changes in brain chemistry. It may even predate the diagnosis.
As many as 40 percent of people with PD will experience some form of anxiety, such as generalized anxiety disorder, anxiety attacks, social avoidance, or obsessive-compulsive disorder. Fortunately, mental health professionals can help by providing effective talk and, when appropriate, drug therapies. In this episode, clinical psychologist Roseanne Dobkin, PhD, Professor of Psychiatry at Rutgers University in New Jersey, discusses the difference between reasonable worry and problematic anxiety and elucidates some of the ways mental health professionals can help when feelings become distressing or all consuming, interfering with day to day life and activities.
- Understanding Parkinson’s: Anxiety
- Fact Sheet: Stress Management for PD
- Episode 78: Benefits of Self Awareness with PD (podcast)
- Episode 80: How Mindfulness Techniques Impact the Nervous System (podcast)
About This Episode
Released: June 30, 2020
Roseanne Dobkin, PhD
Roseanne Dobkin is a licensed clinical psychologist and Professor of Psychiatry at Rutgers University with a well-established clinical research program in the mental health aspects of Parkinson’s disease (PD).
Key objectives of her research program include 1) improving the recognition, assessment and treatment of the neuropsychiatric complications of PD, including cognition, depression, anxiety, and sleep, 2) advancing the understanding of the complex interaction between the motor and non-motor symptoms of PD and the influence of this interaction on course and progression of PD, and 3) utilizing applications of telemedicine to leverage access to informed mental health care for all members of the PD community. To date, her PD research has been funded by the National Institutes of Health, the Patterson Trust Awards Program in Clinical Research, the Michael J. Fox Foundation for Parkinson’s Research, the Parkinson’s Unity Walk, the Parkinson’s Foundation, and the Health Services Research and Development Division (HSR&D; Merit Award) of the Veteran Affairs Administration.
This episode is supported by a grant from Genentech, a member of the Roche Group.
For all of our Substantial Matters podcast episodes, visit parkinson.org/podcast.